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Purpose: To preliminarily test the hypothesis that fluorine 19 (19F) 
magnetic resonance (MR) imaging enables the nonin-
vasive in vivo identification of plaque inflammation in a 
mouse model of atherosclerosis, with histologic findings 
as the reference standard.
Materials and 
Methods:
The animal studies were approved by the local animal 
ethics committee. Perfluorocarbon (PFC) emulsions were 
injected intravenously in a mouse model of atherosclero-
sis (n = 13), after which 19F and anatomic MR imaging 
were performed at the level of the thoracic aorta and its 
branches at 9.4 T. Four of these animals were imaged 
repeatedly (at 2–14 days) to determine the optimal de-
tection time. Repeated-measures analysis of variance with 
a Tukey test was applied to determine if there was a sig-
nificant change in 19F signal-to-noise ratio (SNR) of the 
plaques and liver between the time points. Six animals 
were injected with a PFC emulsion that also contained 
a fluorophore. As a control against false-positive results, 
wild-type mice (n = 3) were injected with a PFC emulsion, 
and atherosclerotic mice were injected with a saline solu-
tion (n = 2). The animals were sacrificed after the last MR 
imaging examination, after which high-spatial-resolution 
ex vivo MR imaging and bright-field and immunofluores-
cent histologic examination were performed.
Results: 19F MR signal was detected in vivo in plaques in the aortic 
arch and its branches. The SNR was found to significantly 
increase up to day 6 (P , .001), and the SNR of all mice 
at this time point was 13.4 6 3.3. The presence of PFC 
and plaque in the excised vessels was then confirmed both 
through ex vivo 19F MR imaging and histologic examina-
tion, while no signal was detected in the control animals. 
Immunofluorescent histologic findings confirmed the pres-
ence of PFC in plaque macrophages.
Conclusion: 19F MR imaging allows the noninvasive in vivo detection of 
inflammation in atherosclerotic plaques in a mouse model 
of atherosclerosis and opens up new avenues for both the 
early detection of vulnerable atherosclerosis and the elu-
cidation of inflammation mechanisms in atherosclerosis.
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In recent years, it has become evi-dent that anatomic predictors, in-cluding high plaque burden and the 
presence of a thin fibrous cap, are by 
themselves not sufficiently specific to 
allow prediction of which atheroscle-
rotic plaques will rupture and lead to 
future events (1). A highly promising 
and complementary strategy for the 
identification and definition of plaque 
vulnerability is the direct visualization 
of inflammation (2). Indeed, the role of 
inflammation at all stages of atheroscle-
rosis is now well established (2), and 
the presence of a macrophage-rich in-
flammation has been linked to plaque 
vulnerability (3).
Fluorine 18 (18F) fluorodeoxyglu-
cose positron emission tomography 
(PET) can, for example, be used for 
the noninvasive and highly sensitive 
imaging of inflammation in atheroscle-
rosis through the uptake of the tracer 
18F fluorodeoxyglucose in a plaque (4). 
However, the tracer requires a cyclo-
tron for production, and its radioac-
tivity renders the technique less suit-
able for long-term disease monitoring. 
Magnetic resonance (MR) imaging, in 
combination with the intravenous injec-
tion of a contrast agent that is phago-
cytized by circulating immune cells, can 
also be used for imaging inflammation 
in atherosclerosis: Several types of 
custom-designed gadolinium- and iron 
oxide–based contrast agents that tar-
get inflammation have been described 
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(5–7) and used for plaque characteriza-
tion. Iron oxide particles have, for ex-
ample, been used in humans to detect 
inflammation in carotid plaques (8) and 
in the myocardium after infarction (9). 
However, these techniques have the 
disadvantage of not being quantitative 
or being custom designed, or they will 
likely remain limited to animal studies 
because of marked regulatory hurdles 
or concerns related to toxicity and 
safety. Therefore, despite their prom-
ise, a translation to human studies still 
appears to be distant.
In this proof-of-principle study, we 
instead propose to use fluorine 19 (19F) 
MR imaging of injected perfluorocar-
bons (PFCs) (10,11) for the visualiza-
tion and quantitative characterization of 
inflammation in atherosclerotic plaque 
in vivo. PFCs are inert, nontoxic carbo-
hydrates in which all hydrogen has been 
replaced with fluorine and of which 
several types have passed through U.S. 
Food and Drug Administration trials 
(12) as blood volume expanders. 19F 
MR imaging has several distinct ad-
vantages over conventional hydrogen 
1 (1H) molecular imaging, which stem 
from the combination of the facts that 
the fluorine atoms in the PFCs are im-
aged directly (in lieu of their effect on 
their surroundings) and that fluorine is 
not naturally abundant in the human 
body at a concentration that is detect-
able with MR imaging. The 19F signal is 
therefore highly specific to the injected 
PFC, and the signal strength is linked to 
its local quantity, which allows the fluo-
rine concentration to be directly quanti-
fied. This means not only that selective 
angiography with high image contrast 
(13) can be performed immediately 
after injection, but also that inflamma-
tion in various disease processes such 
as myocardial infarction (14), arthritis 
(15), and myocarditis (16) can be visu-
alized with high specificity, as evidenced 
in various mouse models. Furthermore, 
post mortem proof-of-principle studies 
have shown that plaques in the human 
carotid artery can be labeled and that 
the PFC nanoparticle concentration 
can be quantified on a nanomolar scale 
(17). Thus, the noninvasive 19F MR 
measurement of the PFC concentration 
in vivo may eventually support the 
quantitative characterization of inflam-
mation in atherosclerosis progression 
over time and may ultimately be used 
to better guide and monitor therapy in 
patients.
For these reasons, we developed 
and implemented a 19F MR imaging 
protocol to preliminarily test the hy-
pothesis that 19F MR imaging enables 
the noninvasive in vivo identification of 
plaque inflammation in a mouse model 
of atherosclerosis, with histologic find-
ings as the reference standard.
Materials and Methods
Animal Protocol
The animal studies were approved by 
the local animal ethics committee. Fif-
teen 8-week-old male apolipoprotein E 
knockout (ApoE2/2) mice (B6.129P2-
ApoE2/2tm1Unc) and three C57Bl/6 wild-
type (WT) mice (all from Charles River 
Laboratories, L’Arbresle, France) were 
fed a high-fat diet (20% milk butter 
and 0.15% cholesterol, Western Diet 
U8958 version 52; Safe Diets, Augy, 
France) for 12 weeks to exacerbate ath-
erosclerosis development and to keep 
experimental conditions as similar as 
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Figure 1
Figure 1: Schematic overview of the experiments. All mice (A = ApoE2/2, WT = WT control) followed 
a high-fat diet, 12 weeks after which they were serially injected with PFC, FITC PFC, or saline. They then 
underwent serial MR imaging or a single session of MR imaging 6 days after the last injection. Immediately 
after the last MR imaging session they were euthanized, which was followed by ex vivo MR imaging and 
histologic examination. Immunofluorescent histologic examination (Immunofluo) was then performed on the 
aortas of the FITC PFC–injected mice.
All MR experiments were performed 
in a 9.4-T horizontal bore animal spec-
trometer (Varian, Palo Alto, Calif). An-
imals underwent isoflurane anesthesia 
(4% in air for induction, followed by 
2% in a mixture of 60% oxygen and 
40% air). Electrocardiographic elec-
trodes were applied to the paws, and 
the animals were placed in a dedicated 
holder on top of a respiration pillow 
and a custom-designed 18-mm–diame-
ter quadrature surface coil that is tun-
able to both the 1H and 19F resonance 
frequencies. The body temperature was 
monitored with a rectal probe (SA In-
struments, Stony Brook, NY) and kept 
constant at 37.0°C 6 0.5 by using tub-
ing with circulating warm water.
Segmented bright-blood 1H gradi-
ent echo images (field of view, 30 3 30 
mm2; section thickness, 1 mm; six sec-
tions acquired; 128 3 128 matrix; reso-
lution, 0.23 3 0.23 3 1 mm3 or 55 nL; 
four signals acquired; repetition time 
msec/echo time msec, 3.9/1.9; acqui-
sition time, approximately 8 minutes) 
were acquired at the level of the tho-
racic aorta and its branches in various 
orientations (sagittal, transverse, and 
oblique coronal to follow the aorta) for 
anatomic localization. This 1H gradient-
echo pulse sequence was triggered with 
both electrocardiography and respira-
tion (SA Instruments) to compensate 
for motion. This was followed by non-
triggered multisection 19F turbo spin-
echo imaging (64 3 64 matrix, resolu-
tion of 0.47 3 0.47 3 1 mm3 or 220 nL, 
360 signals acquired, 1250/4.2, echo 
train length of 16, and acquisition time 
of 30 minutes) at the same anatomic 
level. Here, the signal averaging helped 
suppress any motion artifacts.
MR image analysis was performed 
by R.B.v.H. (with 8 years of experience 
with small-animal MR imaging). Signal-
to-noise ratio (SNR) levels were estab-
lished for several regions to gain insight 
into the time course of signal change 
and the maximal signal strength that 
could be obtained with the technique 
(not to quantify concentrations).The 
SNR of a region of interest was defined 
as the average signal in the region of in-
terest divided by the standard deviation 
of a 10 3 5-mm2 region of noise outside 
possible for the control mice (Fig 1). 
ApoE2/2 mice were selected, since this 
is a well-established model for athero-
sclerosis research and since the size 
of their aortas is on the same order of 
magnitude as that of human coronary 
arteries. A PFC emulsion based on 10% 
wt/vol perfluoro-15-crown-5 ether was 
prepared in-house as described pre-
viously (14). The emulsion contains 
nanoparticles with a mean size of 130 
nm, produces a single spectral line at 
292.8 ppm (18), and contains approxi-
mately 8 3 109 19F atoms per nanopar-
ticle. A PFC injection scheme that was 
estimated to maximize the PFC loading 
in the plaque at the time of MR imaging 
was experimentally developed: Every 3 
days during weeks 10–12 after the start 
of the diet, seven ApoE2/2 mice and the 
three WT mice received 100-mL tail-
vein injections. The rationale for these 
empirically chosen small injections was 
to inject a small but still substantial vol-
ume with a sufficiently large time inter-
val to allow the body to accommodate 
for the increase in blood volume. After 
the 12 weeks, the animals received a 
large PFC injection of 500 mL. Six more 
ApoE2/2 mice received the same injec-
tion protocol with fluorescein isothiocy-
anate (FITC) PFC (15), an emulsion to 
which the fluorophore FITC was added 
to perform histologic validation with 
fluorescence microscopy. Two control 
ApoE2/2 mice were injected with saline 
to characterize the 19F signal that does 
not originate from the injected PFC—
that is, the anesthetic isoflurane (which 
is known to be absorbed in the subcu-
taneous fat [19]).
In Vivo MR Imaging
First, MR images were obtained in four 
PFC-injected ApoE2/2 mice on day 2, 
4, 6, 8, and 14 after the last injection 
to determine the optimal time delay be-
tween injection and imaging, since the 
specific pharmacokinetics of this PFC 
in atherosclerotic plaque are unknown. 
The remaining three PFC-injected ani-
mals, as well as the six FITC PFC–in-
jected animals, the two saline-injected 
ApoE2/2 mice, and the three WT con-
trols underwent imaging 6 days after 
the last injection.
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the mouse body. By using 1H MR im-
ages for visual coregistration, the SNR 
of 19F signal in vessels suspected of 
having atherosclerotic plaque as well as 
the liver was quantified in the unpro-
cessed 19F images of the mice injected 
with PFC. All 19F images were then 
postprocessed for visualization with a 
3-pixel–diameter Gaussian filter and in-
terpolated twice, after which they were 
thresholded at three times the unpro-
cessed background standard deviation 
and directly fused with the 1H images 
in Matlab (Mathworks, Natick, Mass).
In the mice that underwent imag-
ing on multiple days, the 19F SNR of the 
aortic arch and its branches, as well as 
that of the liver, were compared be-
tween the different days to determine 
the optimal time point after which the 
SNR no longer increases significantly in 
the aortic arch and its branches.
Ex Vivo Imaging
All animals were euthanized by means 
of pentobarbital overdose after the 
in vivo MR imaging. Euthanized mice 
were perfused at physiologic pressure 
with phosphate-buffered saline and 
then with buffered formaldehyde via 
an arterial catheter. The aortic arch 
was excised and photographed en face 
with a digital camera (Coolpix; Nikon, 
Düsseldorf, Germany) for visual identi-
fication of plaques and their location by 
M.P. and J.F.A. (with 10 and 15 years 
of experience with mouse dissection and 
histologic analysis, respectively). Sub-
sequently, specimens were stored in a 
2% formaldehyde-in-saline solution and 
placed in the MR imaging unit. To ascer-
tain that the 19F signals originated from 
the aorta and not from adjacent tissue 
or other signal sources at the obtainable 
SNR level in vivo, the same multisection 
1H gradient-echo and 19F turbo spin-
echo sequences as those used for the in 
vivo MR imaging were then performed, 
but with a 128 3 128 matrix and 2880 
signals acquired for the 19F sequence. 
For high-spatial-resolution three-dimen-
sional (3D) visualization of the 19F signal 
in the aorta, 3D 1H (field of view, 20 3 
15 3 10 mm3; 128 3 128 3 64 matrix; 
resolution, 0.16 3 0.12 3 0.16 mm3 or 
2.86 nL; eight signals averaged; 80/2.6; 
and acquisition time, 1.5 hours) and 19F 
(64 3 64 3 32 matrix; resolution, 0.31 3 
0.23 3 0.31 mm3 or 22.9 nL; 640 signals 
averaged; 40/1.5; acquisition time, 14.5 
hours) gradient-echo pulse sequences at 
the same anatomic location were used. 
Both data sets were then interpolated to 
a 512 3 512 3 256 matrix size, semi-
automatically segmented, and fused in 
Matlab (Mathworks).
Histologic Examination
For two mice in each group, the aor-
tic arches and branching vessels were 
embedded in paraffin, and 3-mm-thick 
sections were obtained at the level of 
plaques in the brachiocephalic artery. 
Movat pentachrome staining (20) of lo-
cations where 19F signal was observed 
was then performed for plaque char-
acterization and reference-standard 
comparison with 19F MR imaging by 
M.P. and R.B.v.H. Here, blue indicates 
ground substance, blue-black suggests 
nuclei and elastic fibers, red relates to 
muscle, intense red represents fibrin, 
and green-yellow designates collagen 
and reticulin fibers.
Immunofluorescent staining was 
performed (by C.G., with 9 years of ex-
perience with immunohistochemistry) 
in adjacent sections to confirm the pres-
ence of FITC PFC in macrophages. Sec-
tions were selectively immunostained 
for mouse macrophages with antimouse 
Mac-2 antibody (rat monoclonal anti-
body, Cedarlane, Burlington, Canada). 
The FITC signal was amplified by using 
an anti-FITC antibody (rabbit polyclonal 
antibody; Invitrogen, Grand Island, NY) 
to avoid nonspecific autofluorescence 
contamination. Mac-2 and FITC were 
visualized with Alexa 594 and Alexa 
488 conjugated antibodies (Molecular 
Probes, Eugene, Oregon), respectively. 
Nuclei were stained with 4’,6-diamidi-
no-2-phenylindole (Molecular Probes). 
Imaging was performed by using an Ax-
iovision fluorescence microscope (Carl 
Zeiss, Oberkochen, Germany).
Statistical Analyses
Values were represented as means 6 1 
standard deviation. Repeated-measures 
analysis of variance with a post hoc 
Tukey test was applied to determine 
if there was a significant change in 19F 
SNR of the plaques or liver between 
subsequent imaging days. A P value less 
than .05 was considered to indicate a 
statistically significant difference.
Results
In Vivo Detection of PFC in the Aorta and 
Its Branches with 19F MR Imaging
Small patches of 19F signal were ob-
served in regions where atheroscle-
rotic plaques commonly occur in the 
ApoE2/2 mouse model (21), such as the 
aortic arch, the carotid arteries, and 
the brachiocephalic artery (Fig 2, A, B). 
Marked 19F signal was furthermore 
observed in several repositories of im-
mune cells, such as the liver (Kupffer 
cells), lymph nodes, and spinal cord. 
Signal was also observed in subcutane-
ous fat, but control experiments with 
ApoE2/2 mice that were injected with 
saline instead of PFC confirmed that 
this was isoflurane, which accumulates 
exclusively in subcutaneous fat (19). No 
19F signal was observed in the descend-
ing thoracic aorta of any of the mice. 
PFC-injected WT control mice showed 
no 19F signal at the level of the aorta or 
its branches. However, signal was ob-
served in the liver, lymph nodes, and 
subcutaneous fat, as expected.
19F MR images of the PFC-injected 
ApoE2/2 mice that underwent imaging 
multiple times demonstrated that the 
19F SNR in the aorta and its branches 
no longer significantly increases after 
day 6, when a 117% SNR enhancement 
(P , .001) versus that of day 2 was 
observed (Fig 2, C). Day 6 after PFC 
injection was therefore deemed the 
optimal imaging day for the protocol. 
The mean 19F SNR of all PFC-injected 
ApoE2/2 mice on day 6 was 13.4 6 3.3 
(range, 9.3–17.6) in the aortic arch and 
its branches, while the highest SNR 
(117 6 22) was found in the liver on 
day 8 (P = .005, Fig 2, D).
Ex Vivo Confirmation of PFC in Plaque
Plaques that were identified on the pho-
tographs (Fig 3, A) were also individu-
ally identified on the ex vivo MR images 
(Fig 3, B), which confirmed that the 
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Figure 2
Figure 2: A, Sagittal in vivo 19F and 1H MR images of atherosclerotic plaque in ApoE2/2 mice. The “hot-iron” scale is used for the 19F SNR 
level (inset color bar), which is overlaid on the anatomic 1H images in gray scale. The MR images were obtained through the liver, the side of 
the heart, and the brachiocephalic artery. The left panel shows the anatomic 1H image, the middle panel the processed 19F image, and the right 
panel the fusion of the two. The dotted arrow indicates the atherosclerotic plaque, which was later confirmed by means of ex vivo histologic ex-
amination, but signal intensity can also be observed in the liver because of the Kupffer cells taking up PFC and in the subcutaneous fat from the 
anesthetic isoflurane. B, In another animal, an oblique coronal 19F/1H fusion MR image shows two plaques in the aortic arch. C, Plot of 19F SNR 
in the plaques of the group of mice that underwent imaging multiple times demonstrates that the SNR does not significantly change after day 
6. D, Plot of 19F SNR in the liver shows a similar trend as that in the plaques, albeit with a higher SNR. The SNR was not significantly different 
among consecutive days, and only the increase from day 2 to day 6 was statistically significant in the liver when all days were compared. PCE 
= perfluoro-15-crown-5 ether.
source of the 19F signal was within the 
aortas. Three-dimensional visualiza-
tions of segmented high-spatial-resolu-
tion 3D MR imaging further illustrated 
the location of the PFC deposits in the 
vessel wall (Fig 3, C).
Co-localization of PFC and Immune Cells
Movat pentachrome staining confirmed 
the presence of intermediate plaques at 
the locations of the 19F signal, consistent 
with the disease model (Fig 4, A, B). 
Subsequent immunofluorescent stain-
ing for mouse macrophages (through 
Mac-2) and PFC (through FITC) dem-
onstrated the presence of PFC in 
plaque macrophages through the co-
localization of the fluorescent signals, 
although not all PFC was contained in 
macrophages (Fig 4, C–E). Importantly, 
immunofluorescent staining showed 
no macrophage or 19F signal in the 
WT control mice, while in the control 
ApoE2/2 mice that were injected with 
saline—that is, those without PFC—
only a macrophage signal was detected 
at histologic examination.
Discussion
This study demonstrated the feasibility 
of the in vivo 19F MR imaging detec-
tion of inflammation in atherosclerotic 
plaque, with ex vivo imaging and immu-
nofluorescent histologic findings as the 
reference standard. The technique dif-
fers from previously described MR im-
aging techniques in that the PFC does 
not indirectly modulate an existing sig-
nal like iron oxide (22) or gadolinium 
(23) nanoparticles do but directly gen-
erates the 19F signal itself without the 
presence of background signals. This 
allows for very high specificity and the 
ultimate possibility of direct SNR quan-
tification that is linearly related to the 
present quantity of PFC (17). Since 
there is no need for potentially harmful 
ionizing radiation, and since the PFC 
particles are considered safe (several 
variants have been studied in clinical 
trials) (24), 19F MR imaging appears 
to be well positioned for translation 
into the clinical setting, where it may 
be used to monitor the response of an 
individual patient to a therapy designed 
to decelerate, halt, or reverse plaque 
progression.
Our study had limitations. The PFC 
concentration itself was not quantified 
in this study, since the effects of motion 
compensation through averaging on the 
signal strength has not been studied 
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Figure 3
Figure 3: Ex vivo visualization of atherosclerotic plaques in mouse aortic arches. A, En face photographs of excised aortic arches and their 
branching vessels of a WT control mouse and an ApoE2/2 mouse. Atherosclerotic plaques are observed as white patches in the ApoE2/2 
mouse aorta (arrows). B, 19F/1H MR image of the same control and ApoE2/2 mouse aortas (arrowheads) shows 19F signal intensity in a similar 
pattern (arrows) as the plaques in the photographs, while no 19F signal intensity is observed in the control mouse aorta. Small dark patches on 
the 1H images are caused by trapped microscopic air bubbles. C, High-spatial-resolution 3D rendering of an aorta and its 19F signal intensity 
are shown in a different mouse. Both the inner and outer surface of the aortic wall have been visualized in transparent pink, while the 19F signal 
intensity in orange can be seen to be located on the inner surface of the aortic arch and the brachiocephalic artery.
and since the loading of the used sur-
face radiofrequency coil would need 
to be determined for each mouse in-
dividually (25). A minimum amount of 
labeled immune cells that are needed 
for the signal to be detected is there-
fore difficult to establish, although a 
detection limit of this type of imaging 
protocol was previously reported to be 
approximately 400 cells per voxel (14). 
Considering that no 19F signal was de-
tected in the descending aorta and that 
smaller plaques commonly occur there 
(26), an improved sensitivity might be 
needed to detect very small plaque for-
mations. Fortunately, several avenues 
are available for future improvements, 
such as an optimized PFC administra-
tion scheme; a higher PFC load in the 
emulsion (safe formulations with up to 
30% instead of the 10% used here have 
been reported [27]); the implemen-
tation of novel image reconstruction 
methods, such as compressed sensing 
(28); or the postformulation addition of 
a targeting ligand (29). Furthermore, 
the exact correlation of the 19F MR sig-
nal with the macrophage load as can 
be determined through histologic exam-
ination should be established, while the 
exact populations that internalize PFC 
could be investigated by means of flow 
cytometry.
We found that 6 days after the last 
injection was the optimal time point to 
perform imaging. This time point most 
likely results from a combination of 
both the number and spread of the in-
jection series and the composition and 
clearance rate of the PFC emulsion. 
However, we did not further optimize 
the injection scheme for this proof-of-
principle study. Possible sources of the 
increase in PFC over time are the liver 
and spleen, where the sequestered im-
mune cells retain PFC for several weeks 
(30). The slow increase and decrease 
of 19F signal over time in the liver is 
furthermore consistent with previous 
observations for perfluoro-15-crown-5 
ether (30).
Immunofluorescent histologic re-
sults further demonstrated PFC ab-
sorption by cell types other than 
macrophages, which is in line with 
the findings of other studies (16,31). 
However, since the FITC is covalently 
linked only to the phospholipids in 
the emulsion and not to the perfluoro-
15-crown-5 ether, it should be noted 
that we cannot be certain that these 
two components of the FITC PFC are 
still 100% associated with one an-
other, especially at the later imaging 
time points. Furthermore, contrary 
to nanoparticles that exhibit a certain 
targeting ligand, it currently remains 
to be elucidated how exactly the “pas-
sive” nanoparticles used in this study 
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Figure 4
Figure 4: Histologic images show an intermediate-stage atherosclerotic plaque in a brachiocephalic artery. A, B, Movat pentachrome staining 
(original magnification for A, , 310; original magnification for B, 360) shows that the plaque is characterized by the presence of macrophage 
foam cells (black dotted arrows on B ), a necrotic core (in blue), and a thin fibrous cap. This plaque is located on the inner surface, as also 
observed in the 3D renderings, and occupies approximately (42/152) 3 103 mm2 = 28% of the vessel lumen area. C, D, Immunofluorescence 
staining (original magnification, 363) of the same region of the plaque (area inside the dashed box on B ) demonstrates the presence of PFC 
(FITC in green) and macrophages (Mac-2 in red) in the plaque. Blue indicates cellular nuclei (from 4’,6-diamidino-2-phenylindole). E, Merged 
picture of C and D (original magnification, 363) demonstrates that most of the PFC is contained within the macrophages (solid arrows on 
C–E ). Cells that are not macrophages that absorbed PFC (arrowheads on C and E ) and cells that are not macrophages and did not absorb PFC 
(dotted arrows on C and E ) can also be observed.
migrate into the plaque. They might 
be phagocytized by monocytes in the 
bloodstream that then migrate to the 
plaque, or they might diffuse through 
leaky endothelium via the vasa vaso-
rum or directly into the plaque or by 
a combination of the above. Should a 
higher sensitivity be obtained by using 
advanced methods, such mechanisms 
could be studied in-depth by following 
the fate of injected specific immune 
cell populations that are labeled in vi-
tro (32), which would result in valu-
able new insights into the mechanisms 
of cell turnover in atherosclerosis.
In the clinical realm, the most es-
tablished noninvasive atherosclerosis 
inflammation imaging technique is cur-
rently PET of the injected radioactive 
tracer 18F fluorodeoxyglucose, which 
is used to detect an increase in plaque 
metabolism and has a very high sensi-
tivity, while it also has the advantage 
of being quantifiable (33). However, the 
spatial resolution of PET is inherently 
quite low, it requires a nearby cyclotron, 
and, to provide an anatomic reference 
for such small structures as atheroscle-
rotic plaques, it needs to be overlaid 
on an anatomic computed tomographic 
(CT) or MR image. CT involves another 
dose of potentially harmful ionizing ra-
diation and renders the technique less 
suitable for monitoring disease progres-
sion or therapy, while for the 19F MR 
imaging technique described here, an-
atomic 1H images are readily available 
for coregistration.
Given that 0.5 L of PFC has already 
been injected as a blood volume ex-
pander in humans (12), the dosage in 
this study was deliberately chosen to 
be high to maximize the 19F signal and 
to ensure visualization of the plaque 
inflammation. However, a dose opti-
mization or a study of the absorption 
kinetics has not yet been performed, 
and it can therefore be hypothesized 
that fewer (perhaps even a single) or 
smaller injections may achieve similar 
plaque 19F loading. It should also be 
noted that because of the slow clear-
ance kinetics of the crown ether used 
in this study (30), other PFCs might be 
more suitable for human applications. 
PFCs with a single resonance, such as 
perfluoropolyether (34) or “Perfecta” 
(35), might have different kinetics and 
allow for fewer injections, although 
this remains to be tested. Further-
more, given that the voxel size in hu-
mans is often more than two orders 
of magnitude larger than that used in 
8 radiology.rsna.org n Radiology: Volume 000: Number 0—   2015
EXPERIMENTAL STUDIES: Fluorine MR Imaging of Inflammation in Atherosclerotic Plaque in Vivo van Heeswijk et al
mice here (up to 2 3 2 3 8 mm3 or 
32 mL vs 0.22 mL used in this study), 
a smaller dose may in fact be sufficient 
for initial plaque macrophage visualiza-
tion in human carotid arteries. A quick 
calculation suggests that scaling from 
2.5 mL total blood volume in mice to 5 
L in humans with 10 times larger voxel 
size results in a 100-mL slow infusion 
volume (while the smaller injections 
translate to 20 mL), but this remains 
to be investigated and optimized. Since 
the detection limit of 19F is on the or-
der of 400 mmol/L for gradient-echo 
MR imaging (13), a detection limit 
down to at least 13 nmol per voxel 
might be expected in humans. This rel-
ative signal increase could equally be 
used to improve the sensitivity and to 
reduce the 19F MR imaging time.
In conclusion, we provided a pre-
liminary account of the utility of a safe 
fluorine MR imaging technique for the 
in vivo visualization of inflammation in 
atherosclerosis. This opens a new av-
enue for research and discovery in ath-
erosclerosis on the one hand and may 
ultimately provide a tool to better help 
guide and monitor therapy in patients 
at risk for atherosclerosis or those 
with documented atherosclerosis on the 
other hand.
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